In order to become a big winner in the pharmaceutical investment market competition, pharmaceutical merchants must have a big vision and a big pattern: “How big is the heart and how big the stage is.†If dealers want to make money and make big money, they also need to have great things to do. Vision, with a large trading market pattern of medicine. Big eyes only have big pharmaceutical investment market, big breasts have a big pattern, dealers must have the courage to expand the market, brave as regional, industry, brand first confidence, so that the target generates momentum, dealers can look to the future Only in this way can we plan our own development strategy and play steadily.
However, the medical agent commissioner pointed out that if the process is disconnected from the current situation of pharmaceutical investment enterprises, the process will lose its significance. Acting for investment is also the same reason, only refinement can be done professionally, doing fine, and the chance of success is even greater. Pharmaceutical investment enterprises should combine their own advantages in resources, agents and the company's positioning to match the direction of the product, will be able to contribute. Investing in what scope depends on the fact that pharmaceutical investment promotion companies need to clearly understand their internal resources when investing, rather than empty-hearted. Everyone wants to expand their sales area. It is best to recruit businesses to recruit Taiwan. Of course, in the pharmaceutical investment promotion industry, it is also very important for the pharmaceutical investment enterprise to grasp the customers. Only by letting customers put down their anti-stress, can they “bleach†them.
The pharmaceutical agents pointed out that most current pharmaceutical investment companies do not have the qualification to produce drugs, so they often overlook the shaping of products or corporate brands in the sales process, but only pay attention to the increase in sales volume. This is a very short-sighted behavior. When the state increased regulation and supervision of the market, agents (especially a large number of pharmaceutical and natural persons active in the market) were strongly influenced by the national policies, and their own operating scale and strength fell drastically, and they gradually faded out of the pharmaceutical market and turned to health products. And medical devices; when the competition between enterprises becomes more intense, gradually entering the era of homogenous competition, and facing the quagmire of homogenization of products and homogenization of models and turning into price wars and unable to extricate themselves, pharmaceutical investment enterprises Naturally, there is a bit more blindness, resulting in a phenomenon in which the ratio of input to output is hanging upside down. When this series of factors work together, the efficiency of pharmaceutical investment enterprises is greatly reduced, thus forming a nausea cycle in the size of capital investment and sales, and the development of crisis companies.
The pharmaceutical investment enterprise itself must proceed from the perspective of a service provider. All marketing work is for the pharmaceutical agents to develop and profit. The vast majority of agents attach great importance to the market services provided by enterprises. With the strong support of enterprises and perfect services, agents have more confidence and security, so they can join in with confidence. Therefore, it may be a good idea to show your company's service concept in your pharmaceutical investment advertisement.
With the continuous deepening of medical reform, the external environment of pharmaceutical investment promotion companies is undergoing earth-shaking changes. On the one hand, the state has proposed a more scientific and reasonable concept for the formulation of drug prices, namely, by managing the internal gross margins of enterprises and limiting the external circulation spreads, so that marketing costs that can be operated by investment enterprises can be greatly reduced; on the other hand, the state promulgated in early 2009. The tendering rules once again referred to similar “two-vote system†arguments and encouraged regional pilots, which in turn fundamentally affected the cooperation between companies and pharmaceutical agents. The pharmaceutical investment market has always been a special market with heavy margins that rely on production and alienation operations to achieve profitability. High profitability is accompanied by high risks. This market is now experiencing a short period of pre-prosperity.
As an important part of the pharmaceutical industry system, pharmaceutical investment promotion companies do not directly face the channel to conduct product management because they have no varieties or few varieties. They cannot control their channels to maintain their advantages in resources, even though they act as upstream manufacturers and downstream agents. The status of business is very important, but few companies value their own brand promotion and promotion, and they are often based on the type of agent to build the image. There is nothing wrong with the original intention of this practice, but the hidden dangers for the later period may be enormous. In the opinion of medical agent experts, pharmaceutical investment promotion companies must continuously summarize the business operations of companies in order to improve the effectiveness of their operations. Through the communication of different classes and different objects, the company will issue the most pertinent evaluation of the business activities, and these will be summed up into a book, signed by the person in charge of the company, issued to the relevant personnel involved in the operation, so that all personnel understand Gains and losses, clearly the right and wrong of future work. Eventually through this scientific and rigorous business practices, the effectiveness of the company's operations was improved again and again.
However, the medical agent commissioner pointed out that if the process is disconnected from the current situation of pharmaceutical investment enterprises, the process will lose its significance. Acting for investment is also the same reason, only refinement can be done professionally, doing fine, and the chance of success is even greater. Pharmaceutical investment enterprises should combine their own advantages in resources, agents and the company's positioning to match the direction of the product, will be able to contribute. Investing in what scope depends on the fact that pharmaceutical investment promotion companies need to clearly understand their internal resources when investing, rather than empty-hearted. Everyone wants to expand their sales area. It is best to recruit businesses to recruit Taiwan. Of course, in the pharmaceutical investment promotion industry, it is also very important for the pharmaceutical investment enterprise to grasp the customers. Only by letting customers put down their anti-stress, can they “bleach†them.
The pharmaceutical agents pointed out that most current pharmaceutical investment companies do not have the qualification to produce drugs, so they often overlook the shaping of products or corporate brands in the sales process, but only pay attention to the increase in sales volume. This is a very short-sighted behavior. When the state increased regulation and supervision of the market, agents (especially a large number of pharmaceutical and natural persons active in the market) were strongly influenced by the national policies, and their own operating scale and strength fell drastically, and they gradually faded out of the pharmaceutical market and turned to health products. And medical devices; when the competition between enterprises becomes more intense, gradually entering the era of homogenous competition, and facing the quagmire of homogenization of products and homogenization of models and turning into price wars and unable to extricate themselves, pharmaceutical investment enterprises Naturally, there is a bit more blindness, resulting in a phenomenon in which the ratio of input to output is hanging upside down. When this series of factors work together, the efficiency of pharmaceutical investment enterprises is greatly reduced, thus forming a nausea cycle in the size of capital investment and sales, and the development of crisis companies.
The pharmaceutical investment enterprise itself must proceed from the perspective of a service provider. All marketing work is for the pharmaceutical agents to develop and profit. The vast majority of agents attach great importance to the market services provided by enterprises. With the strong support of enterprises and perfect services, agents have more confidence and security, so they can join in with confidence. Therefore, it may be a good idea to show your company's service concept in your pharmaceutical investment advertisement.
With the continuous deepening of medical reform, the external environment of pharmaceutical investment promotion companies is undergoing earth-shaking changes. On the one hand, the state has proposed a more scientific and reasonable concept for the formulation of drug prices, namely, by managing the internal gross margins of enterprises and limiting the external circulation spreads, so that marketing costs that can be operated by investment enterprises can be greatly reduced; on the other hand, the state promulgated in early 2009. The tendering rules once again referred to similar “two-vote system†arguments and encouraged regional pilots, which in turn fundamentally affected the cooperation between companies and pharmaceutical agents. The pharmaceutical investment market has always been a special market with heavy margins that rely on production and alienation operations to achieve profitability. High profitability is accompanied by high risks. This market is now experiencing a short period of pre-prosperity.
As an important part of the pharmaceutical industry system, pharmaceutical investment promotion companies do not directly face the channel to conduct product management because they have no varieties or few varieties. They cannot control their channels to maintain their advantages in resources, even though they act as upstream manufacturers and downstream agents. The status of business is very important, but few companies value their own brand promotion and promotion, and they are often based on the type of agent to build the image. There is nothing wrong with the original intention of this practice, but the hidden dangers for the later period may be enormous. In the opinion of medical agent experts, pharmaceutical investment promotion companies must continuously summarize the business operations of companies in order to improve the effectiveness of their operations. Through the communication of different classes and different objects, the company will issue the most pertinent evaluation of the business activities, and these will be summed up into a book, signed by the person in charge of the company, issued to the relevant personnel involved in the operation, so that all personnel understand Gains and losses, clearly the right and wrong of future work. Eventually through this scientific and rigorous business practices, the effectiveness of the company's operations was improved again and again.
Chongqing Pangfanyi Technology Co.,Ltd. Can supply with a variety of Aluminum Alloy Die-castings for many years professional experience. The main products are high precision die-castings and machining parts made for those industries which require high quality aluminum alloy die-castings, such as automobile, general machinery, street lighting and medical industries etc. The products are reliable technology, stable in quality, and exported to the United States, Germany ,the Netherlands, Japan, etc.
Aluminum Alloy Petrol-170 Engine Housing
China Chongqing Pangfanyi Technology Co.,Ltd. , https://www.pangfany.com